BidaskClub downgraded shares of K2M Group (NASDAQ:KTWO) from a buy rating to a hold rating in a report published on Saturday.

A number of other analysts have also commented on the stock. Cantor Fitzgerald initiated coverage on shares of K2M Group in a research note on Thursday, May 31st. They set an overweight rating and a $28.00 price objective for the company. Zacks Investment Research lowered shares of K2M Group from a hold rating to a sell rating in a research note on Wednesday, July 4th. Needham & Company LLC upped their price objective on shares of K2M Group from $23.00 to $29.00 and gave the company a buy rating in a research note on Thursday, August 2nd. Oppenheimer set a $25.00 price objective on shares of K2M Group and gave the company a buy rating in a research note on Thursday, August 2nd. Finally, JMP Securities lowered shares of K2M Group from an outperform rating to a market perform rating in a research note on Thursday, August 30th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the company’s stock. K2M Group presently has an average rating of Hold and a consensus target price of $25.90.

Shares of NASDAQ KTWO opened at $27.28 on Friday. K2M Group has a twelve month low of $16.44 and a twelve month high of $27.50. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.48 and a quick ratio of 2.13. The stock has a market capitalization of $1.19 billion, a price-to-earnings ratio of -31.36 and a beta of 1.60.

K2M Group (NASDAQ:KTWO) last issued its quarterly earnings results on Wednesday, August 1st. The medical device company reported ($0.25) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.06). K2M Group had a negative net margin of 14.49% and a negative return on equity of 16.27%. The business had revenue of $73.58 million during the quarter, compared to analyst estimates of $70.85 million. During the same period in the previous year, the company posted ($0.21) earnings per share. K2M Group’s revenue was up 12.0% compared to the same quarter last year. equities research analysts forecast that K2M Group will post -0.77 EPS for the current year.

In other news, CFO Gregory S. Cole sold 1,480 shares of the company’s stock in a transaction dated Thursday, August 16th. The stock was sold at an average price of $20.08, for a total value of $29,718.40. Following the transaction, the chief financial officer now owns 65,659 shares in the company, valued at approximately $1,318,432.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Gregory S. Cole sold 82,304 shares of the company’s stock in a transaction dated Thursday, August 30th. The shares were sold at an average price of $27.40, for a total value of $2,255,129.60. Following the completion of the transaction, the chief financial officer now owns 147,963 shares in the company, valued at approximately $4,054,186.20. The disclosure for this sale can be found here. Insiders have sold 85,346 shares of company stock valued at $2,318,362 over the last ninety days. Insiders own 6.00% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of KTWO. Schwab Charles Investment Management Inc. increased its holdings in shares of K2M Group by 3.0% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 202,289 shares of the medical device company’s stock valued at $3,834,000 after purchasing an additional 5,864 shares during the period. Engineers Gate Manager LP acquired a new position in shares of K2M Group in the 1st quarter valued at about $190,000. Northern Trust Corp increased its holdings in shares of K2M Group by 0.5% in the 1st quarter. Northern Trust Corp now owns 549,513 shares of the medical device company’s stock valued at $10,413,000 after purchasing an additional 2,756 shares during the period. BlackRock Inc. increased its holdings in shares of K2M Group by 2.4% in the 1st quarter. BlackRock Inc. now owns 2,860,772 shares of the medical device company’s stock valued at $54,213,000 after purchasing an additional 66,352 shares during the period. Finally, Oppenheimer Asset Management Inc. increased its holdings in shares of K2M Group by 18.0% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 19,285 shares of the medical device company’s stock valued at $366,000 after purchasing an additional 2,942 shares during the period.

K2M Group Company Profile

K2M Group Holdings, Inc, a medical device company, provides spine and minimally invasive solutions in the United States and internationally. The company offers implants, disposables, and instruments primarily to hospitals for use by spine surgeons to treat spinal pathologies, such as deformity, trauma, and tumor.

Featured Story: Do You Need a Fiduciary?

Analyst Recommendations for K2M Group (NASDAQ:KTWO)

Receive News & Ratings for K2M Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group and related companies with MarketBeat.com's FREE daily email newsletter.